CGRP monoclonal antibody treatment reduced monthly migraine days and improved quality of life in 41 Lithuanian patients over 6 months.
Quality of life improvedBeyond reducing migraine frequency, CGRP antibody treatment improved overall quality of life measures in this Lithuanian cohort
What the researchers found
CGRP monoclonal antibody treatment reduced monthly migraine days and improved quality of life in patients with frequent migraines over a 6-month follow-up period.
Why it matters
Frequent migraines can be debilitating, and many older preventive treatments have limited effectiveness. This real-world data adds to evidence that CGRP-targeting antibodies offer meaningful improvement for people who suffer from chronic migraines.
The numbers in context
41 patients were included, all with 4 or more monthly migraine days lasting more than 3 months. Patients received fremanezumab 225 mg and were followed for 6 months.
How the study worked
Prospective observational study following 41 migraine patients receiving CGRP monoclonal antibody treatment at a university hospital in Lithuania.
Who was studied
Adults with 4+ monthly migraine days at a Lithuanian university hospital
What this study cannot tell us
This was a small pilot study with only 41 patients at a single hospital, without a placebo comparison group. Results may not generalize to other populations.
How to read the evidence
Rated preliminary: small pilot study at a single hospital without placebo control. Provides proof-of-concept real-world data.
When this study was published
Published in 2024. First published data on CGRP antibody use from Lithuania.
The bigger picture
Most CGRP antibody data comes from Western European and North American populations. This study adds evidence from Lithuania, confirming consistent effectiveness across different healthcare systems.
Questions still open
- Would response rates differ with erenumab or galcanezumab?
- How do Lithuanian patients compare to Western European cohorts?
Common questions
Do CGRP antibodies work for frequent migraines?
What is fremanezumab?
Read the original research
The Effect of Calcitonin Gene-Related Peptide Monoclonal Antibodies on Quality of Life among Migraine Patients: Pilot Study at the Hospital of Lithuanian University of Health Sciences Kaunas Clinics.
Acta medica Lituanica, 31(1), 81-91
Citation
Remenčiūtė, Monika; Varžaitytė, Greta; Žemgulytė, Gintarė. (2024). The Effect of Calcitonin Gene-Related Peptide Monoclonal Antibodies on Quality of Life among Migraine Patients: Pilot Study at the Hospital of Lithuanian University of Health Sciences Kaunas Clinics.. Acta medica Lituanica, 31(1), 81-91. https://doi.org/10.15388/Amed.2024.31.1.12